CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease

Journal of Immunology

Volumn 173, Issue 5, 2004, Pages 2933-2941

  Blazar, Bruce R ^a,f   Levy, Robert B ^b   Mak, Tak W ^c   Panoskaltsis Mortari, Angela ^a   Muta, Hiromi ^b,g   Jones, Monica ^b   Roskos, Melinda ^b   Serody, Jonathan S ^d   Yagita, Hideo ^e   Podack, Eckhard R ^b   Taylor, Patricia A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e JUNTENDO UNIVERSITY   (Japan)

^f UNIVERSITY OF MINNESOTA   (United States)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD153 ANTIBODY; CD30 ANTIGEN; CD30 LIGAND; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 4344659974     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.5.2933     Document Type: Article

References (33)

1. Durkop, H., U. Latza, M. Hummel, F. Eitelbach, B. Seed, and H. Stein. 1992. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421.
2. Bowen, M. A., R. K. Lee, G. Miragliotta, S. Y. Nam, and E. R. Podack. 1996. Structure and expression of murine CD30 and its role in cytokine production. J. Immunol 156:442.
3. Shanebeck, K. D., C. R. Maliszewski, M. K. Kennedy, K. S. Picha, C. A. Smith, R. G. Goodwin, and K. H. Grabstein. 1995. Regulation of murine B cell growth and differentiation by CD30 ligand. Eur. J. Immunol. 25:2147.
4. Gilfillan, M. C., P. J. Noel, E. R. Podack, S. L. Reiner, and C. B. Thompson. 1998. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J. Immunol. 160:2180.
5. Smith, C. A., H. J. Gruss, T. Davis, D. Anderson, T. Farrah, E. Baker, G. R. Sutherland, C. I. Brannan, N. G. Copeland, N. A. Jenkins, et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349.
6. Duckett, C. S., and C. B. Thompson. 1997. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 11:2810.
7. Kurts, C., F. R. Carbone, M. F. Krummel, K. M. Koch, J. F. Miller, and W. R. Heath. 1999. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398:341.
8. Telford, W. G., S. Y. Nam, E. R. Podack, and R. A. Miller. 1997. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell. Immunol. 182:125.
9. Amakawa, R., A. Hakem, T. M. Kundig, T. Matsuyama, J. J. Simard, E. Timms, A. Wakeham, H. W. Mittruecker, H. Griesser, H. Takimoto, et al. 1996. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84:551.
10. Chiarle, R., A. Podda, G. Prolla, E. R. Podack, G. J. Thorbecke, and G. Inghirami. 1999. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J. Immunol. 163:194.
11. Muta, H., L. H. Boise, L. Fang, and E. R. Podack. 2000. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J. Immunol. 165:5105.
12. Grell, M., G. Zimmermann, E. Gottfried, C. M. Chen, U. Grunwald, D. C. Huang, Y. H. Wu Lee, H. Durkop, H. Engelmann, P. Scheurich, et al. 1999. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-RI activation by endogenous membrane-anchored TNF. EMBO J. 18:3034.
13. DeYoung, A. L., O. Duramad, and A. Winoto. 2000. The TNF receptor family member CD30 is not essential for negative selection. J. Immunol. 165:6170.
14. Shimozato, O., K. Takeda, H. Yagita, and K. Okumura. 1999. Expression of CD30 ligand (CD153) on murine activated T cells. Biochem Biophys. Res. Commun. 256:519.
15. Wiley, S. R., R. G. Goodwin, and C. A. Smith. 1996. Reverse signaling via CD30 ligand. J. Immunol. 157:3635.
16. + B cells. J. Immunol. 165:786.
17. + tumors. J. Clin. Oncol. 15:3355.
18. Gattei, V., M. Degan, A. Gloghini, A. De Iuliis, S. Improta, F. M. Rossi, D. Aldinucci, V. Perin, D. Serraino, R. Babare, et al. 1997. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89:2048.
19. Cerutti, A., L. Trentin, R. Zambello, R. Sancetta, A. Milani, C. Tassinari, F. Adami, C. Agostini, and G. Semenzato. 1996. The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. J. Immunol. 157:1854.
20. + T cells producing Th2-type cytokines. FASEB J. 9:81.
21. + T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 96:2973.
22. Blazar, B. R., P. A. Taylor, A. Panoskaltsis-Mortari, A. H. Sharpe, and D. A. Vallera. 1999. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 162:6368.
23. Panoskaltsis-Mortari, A., A. Price, J. R. Hermanson, E. Taras, C. Lees, J. S. Serody, and B. R. Blazar. 2004. In vivo imaging of graft-versus-host- disease in mice. Blood 103:3590.
24. Martinez, O. M., J. Villanueva, S. Abtahi, P. R. Beatty, C. O. Esquivel, and S. M. Krams. 1998. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 65:1240.
25. Chan, K. W., C. D. Hopke, S. M. Krams, and O. M. Martinez. 2002. CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J. Immunol. 169:1784.
26. - accessory cells costimulate primed CD4 T cells through OX40 and CD30 at sites where T cells collaborate with B cells. Immunity 18:643.
27. Alzona, M., H. M. Jack, R. I. Fisher, and T. M. Ellis. 1994. CD30 defines a subset of activated human T cells that produce IFN-γ and IL-5 and exhibit enhanced B cell helper activity. J. Immunol. 153:2861.
28. + T cells by IL-4 and IFN-γ. J. Immunol. 158:2090.
29. Harlin, H., E. Podack, M. Boothby, and M. L. Alegre. 2002. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J. Immunol. 169:2451.
30. + T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64:571.
31. Graubert, T. A., J. F. DiPersio, J. H. Russell, and T. J. Ley. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100:904.
32. + donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 98:390.
33. Murai, M., H. Yoneyama, T. Ezaki, M. Suematsu, Y. Terashima, A. Harada, H. Hamada, H. Asakura, H. Ishikawa, and K. Matsushima. 2003. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat. Immunol. 4:154.